NCT04358432 - A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia | Biotech Hunter

Enrollment

262

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

February 25, 2021

Study Completion Date

February 25, 2021

Conditions

Hypercholesterolemia

Interventions

DRUG

AK102

Administered by subcutaneous injection

DRUG

Placebos

Administered by subcutaneous injection

DRUG

Statins and/or Ezetimibe

Lipid-lowering therapies

Trial Locations (2)

Zhong Shan Hosipital Fu Dan University, Shanghai

Affiliated hospital of Guangdong medical university, Zhanjiang